11,540 Exelixis, Inc. $EXEL Shares Purchased by Vise Technologies Inc.

Vise Technologies Inc. raised its position in Exelixis, Inc. (NASDAQ:EXEL) by 73.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,248 shares of the biotechnology company’s stock after buying an additional 11,540 shares during the period. Vise Technologies Inc.’s holdings in Exelixis were worth $1,592,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Exelixis during the 2nd quarter valued at $1,581,991,000. Caisse de depot et placement du Quebec bought a new position in shares of Exelixis in the 2nd quarter valued at about $113,951,000. Bank of New York Mellon Corp acquired a new stake in Exelixis during the 2nd quarter worth $107,803,000. Jupiter Topco LLC acquired a new stake in shares of Exelixis during the second quarter worth $67,299,000. Finally, First Trust Advisors LP increased its stake in shares of Exelixis by 62.0% in the 1st quarter. First Trust Advisors LP now owns 2,534,992 shares of the biotechnology company’s stock valued at $108,726,000 after acquiring an additional 970,144 shares during the last quarter. 85.27% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $53.66, for a total transaction of $526,511.92. Following the completion of the transaction, the director owned 16,079 shares in the company, valued at approximately $862,799.14. This represents a 37.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is owned by company insiders.

Exelixis Stock Up 1.3%

EXEL traded up $0.86 during trading on Friday, hitting $69.57. The company had a trading volume of 2,003,585 shares, compared to its average volume of 2,563,320. The company has a market capitalization of $16.98 billion, a PE ratio of 20.83, a PEG ratio of 1.94 and a beta of 0.45. Exelixis, Inc. has a one year low of $39.71 and a one year high of $73.69. The firm’s 50-day moving average price is $60.92 and its 200 day moving average price is $51.57.

Exelixis (NASDAQ:EXEL) last released its earnings results on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.05. The firm had revenue of $658.70 million during the quarter, compared to analysts’ expectations of $646.51 million. Exelixis had a return on equity of 45.54% and a net margin of 35.45%. The company’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.78 EPS. Sell-side analysts forecast that Exelixis, Inc. will post 3.42 earnings per share for the current year.

Analyst Ratings Changes

EXEL has been the subject of a number of recent analyst reports. Royal Bank Of Canada upped their price objective on shares of Exelixis from $51.00 to $58.00 and gave the company a “sector perform” rating in a research report on Friday, October 30th. Stifel Nicolaus boosted their target price on Exelixis from $47.00 to $51.00 and gave the company a “hold” rating in a research note on Thursday, August 6th. William Blair reissued an “outperform” rating on shares of Exelixis in a research note on Friday, September 11th. Morgan Stanley increased their price target on Exelixis from $53.00 to $60.00 and gave the stock an “equal weight” rating in a report on Friday, October 30th. Finally, Weiss Ratings upgraded Exelixis from a “buy (a-)” rating to a “buy (a)” rating in a report on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $58.85.

About Exelixis

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.